Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Regencell Bioscience Holdings Ltd

Company price
4.18 USD -0.18 ( 4.13%)
Last update at 2026-11-20T21:00:00Z
VOLUME
110449
Market Cap
65.06M

Momentum Score

…

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.12
Low
4.43
High
52 Week Price Range
3.16
Low
30.49
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Regencell Bioscience Holdings Ltd is a small-cap biotechnology company listed on NASDAQ; public disclosures about its specific programs and financials are limited or fragmented, so detailed product descriptions are not widely available. Its long-term growth may depend on clinical progress, regulatory approvals, strategic partnerships and successful commercialization of any therapeutic candidates, which could support upside for investors seeking early-stage biotech exposure.
The most important investment risks include early-stage clinical and regulatory uncertainty, limited public information and market liquidity, and the potential need for additional financing that could dilute existing shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.36
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.04
ROE
-41.71%
Net Debt
-1.10M
ROCE
-52.22%
Diluted EPS TTM
-0.45

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.06M -7.59M -1.35M -0.81M -0.39M
Minority interest 0.19M 0.15M - - -
Net income -5.87M -7.42M -1.35M -0.81M -0.39M
Selling general administrative 4.43M 5.08M 0.94M 0.31M 0.16M
Selling and marketing expenses 0.26M 0.03M 0.00M 0.11M 0.00M
Reconciled depreciation 0.77M 0.60M 0.03M 0.01M 0.00M
Ebit -6.27M -7.62M -1.38M -0.81M -0.39M
Ebitda -5.50M -7.01M -1.35M -0.80M -0.39M
Depreciation and amortization 0.77M 0.60M 0.03M 0.01M -
Operating income -6.27M -7.62M -1.38M -0.81M -0.39M
Other operating expenses 6.27M 7.62M 1.38M 0.81M 0.39M
Interest expense - 0.02M 0.00M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Income tax expense -0.19M -0.17M -0.03M - -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 6.27M 7.62M 1.38M 0.81M 0.39M
Total other income expense net 0.21M 0.02M 0.03M - -
Net income from continuing ops -6.06M -7.59M -1.35M -0.81M -0.39M
Net income applicable to common shares - -7.45M -1.35M -0.81M -0.39M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 12.62M 18.02M 0.34M 0.51M 0.24M
Other current assets - 0.03M 0.01M - -
Total liab 0.63M 0.94M 4.34M 3.16M 2.08M
Total stockholder equity 12.03M 17.07M -4.00M -2.65M -1.84M
Deferred long term liab - - 0.17M - -
Other current liab 0.17M 0.17M 0.66M 0.10M -
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -17.32M -11.44M -4.00M -2.65M -1.84M
Other assets - 0.11M 0.19M 0.02M -
Cash 1.56M 6.42M 0.06M 0.39M 0.24M
Total current liabilities 0.61M 0.58M 4.34M 3.16M 2.08M
Net debt -1.10M -5.65M 3.62M 2.68M 1.84M
Short term debt 0.44M 0.41M 3.68M 3.07M 2.08M
Short long term debt - - 3.68M 3.07M 2.08M
Short long term debt total 0.46M 0.77M 3.68M 3.07M 2.08M
Other stockholder equity 29.43M 28.51M 0.00M 0.00M 0.00M
Property plant equipment - 1.46M 0.08M 0.11M -
Total current assets 11.62M 16.44M 0.07M 0.39M 0.24M
Net tangible assets - 17.07M -4.00M -2.65M -1.84M
Short term investments 10.00M 10.00M - - -
Net receivables 0.06M 0.03M 0.01M - -
Inventory - -0.03M -0.01M - -
Accumulated other comprehensive income -0.09M - - -0.01M -
Common stock total equity - - - 0.00M 0.00M
Non currrent assets other 0.11M 0.11M 0.19M 0.02M -
Non current assets total 1.00M 1.57M 0.27M 0.13M 0.00M
Capital lease obligations 0.46M 0.77M - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 0.06M -10.00M -10.00M -0.12M -10.00M
Change to liabilities - 0.00M 0.00M 0.00M 0.00M
Total cashflows from investing activities - -10.78M -10.78M -0.12M -0.12M
Net borrowings - -0.43M 0.61M 0.99M 0.48M
Total cash from financing activities 0.13M 22.41M 0.44M 0.99M 0.48M
Change to operating activities - -1.02M 0.55M 0.08M 0.08M
Net income -6.06M -7.59M -1.35M -0.81M -0.39M
Change in cash -4.85M 6.36M -0.33M 0.14M 0.09M
Begin period cash flow 6.42M 0.06M 0.39M 0.24M 0.15M
End period cash flow 1.56M 6.42M 0.06M 0.39M 0.24M
Total cash from operating activities -4.96M -5.27M -0.77M -0.73M -0.39M
Issuance of capital stock 0.00M 22.67M - - -
Depreciation 0.77M 0.60M 0.03M 0.01M 0.01M
Other cashflows from financing activities 0.13M -0.27M 0.44M -0.12M 0.48M
Change to netincome - 2.60M 2.75M 2.75M 2.75M
Capital expenditures 0.03M 0.78M 0.78M 0.12M 0.12M
Change in working capital -0.51M -1.02M 0.55M 0.08M 0.00M
Stock based compensation 0.92M 2.76M - - -
Other non cash items -0.09M -0.01M - - -
Free cash flow -4.99M -6.05M -0.77M -0.84M -0.39M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RGC
Regencell Bioscience Holdings Ltd
-0.18
4.13%
4.18 - - - 4.12 -6.99
MKKGY
Merck KGaA ADR
-0.68
2.09%
31.83 21.25 14.93 3.10 2.14 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
163.45 24.86 15.11 3.13 1.98 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
0.38
1.77%
21.79 - 10.96 0.01 1.20 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.05 - 10.66 0.01 1.16 23.11

Profile*

Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Chinachem Leighton Plaza, Causeway Bay, Hong Kong

852 2155 0823

12

Name Title Year Born
Mr. Yat-Gai Au Founder, Chairman & CEO 1973
Ms. Michelle Chan Financial Controller NA
Mr. Wai Hong Chung COO & Chief Strategy Officer 1977
Dr. Yi-Chung Chao Ph.D. Chief Medical Officer & Director 1964
Mr. Tien Hsiang Chau Exec. Officer 1970
Dr. Yi-Chung Chao Ph.D. Special Advisor & Director 1964
Mr. Tien Hsiang Chau Executive Officer 1970
Ms. Antonia Assang Senior Vice President of Project Management NA
Mr. Yat-Pui Au Chief Business Officer 1974

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…